Non-clinical safety assessment of ORC-13661 to support aminoglycoside induced hearing loss indication
Ended Awarded Last action
- Contract number
- 75N95022F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $268,799
Award facts
- Opportunity
-
- 75N95022R00088 Solicitation number
- Contract value 100% obligated
- $268,799.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $65,740 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $203,059 |
About this award
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $268,799.00 delivery order contract to Sri International for non-clinical safety assessment of ORC-13661 to support aminoglycoside induced hearing loss indication. Sri International will perform the work as the prime contractor in West Menlo Park, California from September 14, 2022 through November 13, 2023. Bioivt, LLC will serve as a subcontractor providing a substrate transporter study in support of the prime contractor's work.
Quick answers
Who was awarded contract 75N95022F00001?
75N95022F00001 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on September 14, 2022.
How much is contract 75N95022F00001 worth?
The government has obligated $268,799 on 75N95022F00001.
Which agency awarded contract 75N95022F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95022F00001 an order under another contract?
Yes. 75N95022F00001 is a delivery order under HHSN271201700014I, an indefinite delivery contract, on CRO Support for NCATS In Vitro and In Vivo Toxicology Studies.
Was contract 75N95022F00001 competed?
The extent of competition for 75N95022F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award